



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Labetuzumab govitecan

Cat. No.:	HY-P99681
CAS No.:	1469876-18-3
Target:	Antibody-Drug Conjugates (ADCs)
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Labetuzumab govitecan

BIOLOGICAL ACTIVITY

Description	Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer ^{[1][2][3]} .																
In Vivo	<p>Labetuzumab govitecan (total of 1.0 mg, i.p.) prolongs median survival of GW-39 lung metastatic mouse model^[2]. Labetuzumab govitecan (25 mg/kg, i.p., twice weekly for 4 weeks) prolongs median survival of sc LS174T Xenograft in nude mice^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>sc LS174T Xenograft in nude mice</td> </tr> <tr> <td>Dosage:</td> <td>25 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p. twice weekly for 4 weeks</td> </tr> <tr> <td>Result:</td> <td>Prolonged median survival.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>LS174T tumor xenograft model in nude mice (PK assay)</td> </tr> <tr> <td>Dosage:</td> <td>0.25 mg</td> </tr> <tr> <td>Administration:</td> <td>i.v.</td> </tr> <tr> <td>Result:</td> <td>T_{1/2}: 112.5 h; C_{max}: 115 µg/mL; MRT: 147 h.</td> </tr> </table>	Animal Model:	sc LS174T Xenograft in nude mice	Dosage:	25 mg/kg	Administration:	i.p. twice weekly for 4 weeks	Result:	Prolonged median survival.	Animal Model:	LS174T tumor xenograft model in nude mice (PK assay)	Dosage:	0.25 mg	Administration:	i.v.	Result:	T _{1/2} : 112.5 h; C _{max} : 115 µg/mL; MRT: 147 h.
Animal Model:	sc LS174T Xenograft in nude mice																
Dosage:	25 mg/kg																
Administration:	i.p. twice weekly for 4 weeks																
Result:	Prolonged median survival.																
Animal Model:	LS174T tumor xenograft model in nude mice (PK assay)																
Dosage:	0.25 mg																
Administration:	i.v.																
Result:	T _{1/2} : 112.5 h; C _{max} : 115 µg/mL; MRT: 147 h.																

REFERENCES

- [1]. Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. *J Clin Oncol*. 2017 Oct 10;35(29):3338-3346.
- [2]. Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. *Mol Pharm*. 2015 Jun 1;12(6):1836-47.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA